 ATLANTA--BUSINESS WIRE--- VIRI IASP2021--Virios Therapeutics, Inc. Nasdaq: VIRI, a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that data from the companys Phase 2a clinical trial PRID-201 demonstrated that IMC-1 was better tolerated than placebo in patients with fibromyalgia FM. This result is highlighted in a poster presentation at the International Association fo 